Renaissance Technologies LLC Boosts Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Renaissance Technologies LLC raised its stake in MiMedx Group, Inc. (NASDAQ:MDXG) by 18.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,804,557 shares of the company’s stock after buying an additional 280,327 shares during the period. Renaissance Technologies LLC’s holdings in MiMedx Group were worth $17,360,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. IMG Wealth Management Inc. bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $28,000. Van ECK Associates Corp bought a new stake in MiMedx Group during the 4th quarter valued at $40,000. AlphaQuest LLC purchased a new stake in shares of MiMedx Group in the 4th quarter worth $88,000. Koss Olinger Consulting LLC bought a new position in shares of MiMedx Group during the 4th quarter worth $100,000. Finally, Savant Capital LLC purchased a new position in shares of MiMedx Group during the fourth quarter valued at $100,000. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $6.84 on Monday. The company has a market capitalization of $1.01 billion, a PE ratio of 12.44 and a beta of 1.74. The company has a 50-day simple moving average of $7.86 and a two-hundred day simple moving average of $8.00. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now directly owns 440,178 shares in the company, valued at approximately $3,473,004.42. The trade was a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.